Literature DB >> 16672373

Langerhans cells cross-present antigen derived from skin.

Patrizia Stoitzner1, Christoph H Tripp, Andreas Eberhart, Kylie M Price, Jae Y Jung, Laura Bursch, Franca Ronchese, Nikolaus Romani.   

Abstract

Dendritic cells (DC) efficiently cross-present exogenous antigen on MHC class I molecules to CD8+ T cells. However, little is known about cross-presentation by Langerhans cells (LC), the DCs of the epidermis. Therefore, we investigated this issue in detail. Isolated murine LCs were able to cross-present soluble ovalbumin protein on MHC-class I molecules to antigen-specific CD8+ T cells, albeit less potently than the CD8+ DC subsets from spleen. Furthermore, LCs cross-presented cell-associated ovalbumin peptide and protein expressed by neighboring keratinocytes. Use of transporter associated with antigen processing (TAP-1)-deficient mice suggested a TAP-dependent pathway. Similar observations were made with migratory LC. Antigen expressed in the epidermis was ingested by LCs during migration from the epidermis and presented to antigen-specific T cells in vitro. Cross-presentation of ovalbumin protein by LCs induced IFN-gamma production and cytotoxicity in antigen-specific CD8+ T cells. Additionally, epicutaneous application of ovalbumin protein induced in vivo proliferation of OT-I T cells in the draining lymph nodes; this was markedly enhanced when antigen was applied to inflamed, barrier-disrupted skin. Thus, LCs cross-present exogenous antigen to CD8+ T cells and induce effector functions, like cytokine production and cytotoxicity, and may thereby critically contribute in epicutaneous vaccination approaches.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16672373      PMCID: PMC1472522          DOI: 10.1073/pnas.0509307103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  Cross-presentation, dendritic cells, tolerance and immunity.

Authors:  W R Heath; F R Carbone
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.

Authors:  J L Pooley; W R Heath; K Shortman
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

3.  Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity.

Authors:  Nicholas S Wilson; Georg M N Behrens; Rachel J Lundie; Christopher M Smith; Jason Waithman; Louise Young; Simon P Forehan; Adele Mount; Raymond J Steptoe; Ken D Shortman; Tania F de Koning-Ward; Gabrielle T Belz; Francis R Carbone; Brendan S Crabb; William R Heath; Jose A Villadangos
Journal:  Nat Immunol       Date:  2006-01-15       Impact factor: 25.606

4.  Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.

Authors:  N Seo; Y Tokura; T Nishijima; H Hashizume; F Furukawa; M Takigawa
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

5.  Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression.

Authors:  Alexander D McLellan; Michaela Kapp; Andreas Eggert; Christian Linden; Ursula Bommhardt; Eva-B Bröcker; Ulrike Kämmerer; Eckhart Kämpgen
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

6.  Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin.

Authors:  Gudrun Ratzinger; Patrizia Stoitzner; Susanne Ebner; Manfred B Lutz; Guy T Layton; Christian Rainer; Robert M Senior; J Michael Shipley; Peter Fritsch; Gerold Schuler; Nikolaus Romani
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

7.  A spontaneous CD8 T cell-dependent autoimmune disease to an antigen expressed under the human keratin 14 promoter.

Authors:  Maureen A McGargill; Dita Mayerova; Heather E Stefanski; Brent Koehn; Evan A Parke; Stephen C Jameson; Angela Panoskaltsis-Mortari; Kristin A Hogquist
Journal:  J Immunol       Date:  2002-08-15       Impact factor: 5.422

8.  Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.

Authors:  Yasuhiro Nagata; Satoru Ono; Mitsutoshi Matsuo; Sacha Gnjatic; Danila Valmori; Gerd Ritter; Wendy Garrett; Lloyd J Old; Ira Mellman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-23       Impact factor: 11.205

9.  CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

Authors:  J M den Haan; S M Lehar; M J Bevan
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

10.  Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2.

Authors:  Xinyan Zhao; Eszter Deak; Kelly Soderberg; Melissa Linehan; David Spezzano; Jia Zhu; David M Knipe; Akiko Iwasaki
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

View more
  79 in total

1.  Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination.

Authors:  Irlanda Olvera-Gomez; Sara E Hamilton; Zhengguo Xiao; Carla P Guimaraes; Hidde L Ploegh; Kristin A Hogquist; Liangchun Wang; Stephen C Jameson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 2.  Dietary agents in cancer prevention: an immunological perspective.

Authors:  Ya Ying Zheng; Bharathi Viswanathan; Pravin Kesarwani; Shikhar Mehrotra
Journal:  Photochem Photobiol       Date:  2012-03-30       Impact factor: 3.421

3.  The Langerhans cell controversy: are they immunostimulatory or immunoregulatory cells of the skin immune system?

Authors:  Patrizia Stoitzner
Journal:  Immunol Cell Biol       Date:  2010 May-Jun       Impact factor: 5.126

4.  Langerin, the "Catcher in the Rye": an important receptor for pathogens on Langerhans cells.

Authors:  Patrizia Stoitzner; Nikolaus Romani
Journal:  Eur J Immunol       Date:  2011-09       Impact factor: 5.532

Review 5.  The contribution of Langerhans cells to cutaneous malignancy.

Authors:  Julia Lewis; Renata Filler; Debra A Smith; Kseniya Golubets; Michael Girardi
Journal:  Trends Immunol       Date:  2010-11-09       Impact factor: 16.687

6.  Self-Antigen Presentation by Keratinocytes in the Inflamed Adult Skin Modulates T-Cell Auto-Reactivity.

Authors:  Michael Meister; Amel Tounsi; Evelyn Gaffal; Tobias Bald; Maria Papatriantafyllou; Julia Ludwig; Georg Pougialis; Felix Bestvater; Luisa Klotz; Gerhard Moldenhauer; Thomas Tüting; Günter J Hämmerling; Bernd Arnold; Thilo Oelert
Journal:  J Invest Dermatol       Date:  2015-04-02       Impact factor: 8.551

Review 7.  In vivo function of Langerhans cells and dermal dendritic cells.

Authors:  Daniel H Kaplan
Journal:  Trends Immunol       Date:  2010-10-28       Impact factor: 16.687

8.  The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture.

Authors:  Petra Schnorrer; Georg M N Behrens; Nicholas S Wilson; Joanne L Pooley; Christopher M Smith; Dima El-Sukkari; Gayle Davey; Fiona Kupresanin; Ming Li; Eugene Maraskovsky; Gabrielle T Belz; Francis R Carbone; Ken Shortman; William R Heath; Jose A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-28       Impact factor: 11.205

9.  Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines.

Authors:  Eynav Klechevsky; Maochang Liu; Rimpei Morita; Romain Banchereau; Luann Thompson-Snipes; A Karolina Palucka; Hideki Ueno; Jacques Banchereau
Journal:  Hum Immunol       Date:  2009-02-21       Impact factor: 2.850

Review 10.  Endogenous and tumour-derived microRNAs regulate cross-presentation in dendritic cells and consequently cytotoxic T cell function.

Authors:  Siambi Kikete; Xiaoqian Chu; Li Wang; Yuhong Bian
Journal:  Cytotechnology       Date:  2016-05-18       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.